Zynteglo is a one-time treatment for a blood disorder known as beta thalassaemia in patients 12 years and older who require regular blood transfusions. It is a gene therapy that uses a viral vector (or modified virus) to deliver a working gene into the patient’s blood cells. Zynteglo was granted conditional marketing authorisation in May 2019, which means that the company will provide more evidence about the medicine to EMA for review.